Ataxia-Telangiectasia

ATM Gene Function and DNA Damage Response

• The ATM gene encodes a serine/threonine protein kinase essential for detecting and responding to double-strand DNA breaks (DSBs)
• ATM is activated by ionizing radiation and oxidative stress, initiating cell cycle checkpoints (G1/S and G2/M arrest)
• ATM phosphorylates critical downstream targets including p53, CHK2, and BRCA1, which trigger DNA repair or apoptosis
• Loss of functional ATM protein results in failure to detect and properly respond to DNA damage, allowing accumulation of unrepaired mutations

Cerebellar and Neurological Degeneration

• Primary pathology involves selective vulnerability of Purkinje cells and other cerebellar neurons to accumulated DNA damage
• Defective cell cycle checkpoints allow damaged cells to proceed through mitosis, leading to neuronal apoptosis and progressive loss of cerebellar function
• The cerebellum's high metabolic demands and limited regenerative capacity make it particularly susceptible to ATM deficiency
• Oxidative stress accumulation in neurons contributes to mitochondrial dysfunction and additional cellular injury
• Progressive degeneration extends to basal ganglia, substantia nigra, and dorsal root ganglia, causing broader neurological compromise

Immunodeficiency Mechanism

• T-cell lymphocytes are particularly sensitive to ATM deficiency due to V(D)J recombination, which intentionally creates DSBs during immune receptor gene rearrangement
• Defective ATM function impairs proper resolution of V(D)J recombination, leading to thymic hypoplasia, reduced T-cell numbers, and impaired T-cell function
• B-cell development is also affected, resulting in hypogammaglobulinemia or agammaglobulinemia in many patients
• Natural killer (NK) cell function is compromised, reducing innate immune surveillance
• Combined T-cell and B-cell defects create vulnerability to opportunistic infections and malignancy

Genomic Instability and Cancer Predisposition

• Unrepaired DNA damage accumulates with each cell division, creating a high mutation burden
• Dysfunctional p53 pathway (ATM normally phosphorylates p53 to trigger apoptosis of irreparably damaged cells) allows survival of oncogenic clones
• A-T patients have approximately 100-fold increased risk of malignancy, particularly lymphomas (T-cell and B-cell), gastric cancer, and breast cancer
• Patients show remarkable radiosensitivity due to inability to repair ionizing radiation-induced DNA damage

Endocrine and Metabolic Abnormalities

• Insulin resistance and glucose intolerance develop in up to 80% of patients due to pancreatic beta-cell dysfunction and impaired insulin secretion
• Delayed sexual maturation and hypogonadism result from gonadal dysfunction and hypothalamic-pituitary involvement
• Growth hormone deficiency and growth retardation are common

Genetic Basis

• Autosomal recessive inheritance of ATM gene mutations (chromosome 11q22-23); over 600 different mutations identified worldwide
• Mutations include point mutations, deletions, and insertions; most are loss-of-function variants
• Homozygous or compound heterozygous genotypes required for disease manifestation
• Heterozygous carriers (approximately 1% of population) show modestly increased cancer risk and may have subclinical DNA repair defects

Risk Factors for Clinical Manifestation

• Consanguinity increases prevalence of homozygous ATM mutations
• Early life infections and environmental exposures (oxidative stressors) may accelerate symptom progression
• Ionizing radiation exposure dramatically worsens neurological outcomes and dramatically increases malignancy risk

Neurological Manifestations

• Gait ataxia typically appears by age 2–3 years; progressive and severely disabling
• Titubation (truncal tremor), dysmetria, dysdiadochokinesia, and nystagmus characterize the syndrome
• Dysarthria develops progressively with cerebellar involvement
• By second decade, most patients require wheelchair assistance; profound disability by adulthood

• Ocular apraxia (impaired voluntary eye movements with preserved reflex movements) is present in 90% of patients
• Patients compensate by using head thrusts (head thrust strategy) to redirect gaze rather than moving eyes smoothly
• Supranuclear gaze palsy develops later in disease course
• Nystagmus may develop secondary to cerebellar degeneration

• Extrapyramidal features: dystonia, rigidity, and parkinsonian symptoms may emerge
• Lower motor neuron involvement: progressive weakness, muscle atrophy, and fasciculations reflecting spinal cord degeneration
• Sensory deficits: vibration and proprioception loss (dorsal column and dorsal root ganglia pathology)
• Cognitive decline is variable but can occur; intellectual disability is not typical unless severe early-onset disease

Dermatological Manifestations

• Telangiectasias (dilated small blood vessels) appear on conjunctivae and skin as pathognomonic finding, typically appearing by age 4–10 years
• Conjunctival telangiectasias are present in 90% of patients and are often the first vascular manifestation
• Facial telangiectasias appear on ears, cheeks, and nose
• Premature graying of hair and poliosis (patchy hair depigmentation)
• Cutaneous manifestations generally do not cause functional impairment but serve as clinical marker

Immunological Manifestations

• Recurrent infections affecting sinuses, lungs, and ears; sinopulmonary disease is leading cause of morbidity
• Chronic or recurrent bronchitis, bronchiectasis, and interstitial lung disease
• Recurrent otitis media and sinusitis
• Opportunistic infections (PCP, CMV, atypical mycobacteria) in severely immunocompromised patients
• Autoimmune phenomena: autoimmune hemolytic anemia, thyroid disease, inflammatory bowel disease

Metabolic and Endocrine Manifestations

• Type 2 diabetes mellitus or glucose intolerance in approximately 80% of patients; often requiring insulin therapy
• Growth retardation and short stature
• Delayed or absent sexual maturation; hypogonadism
• Elevated serum alpha-fetoprotein (AFP) levels (not indicative of malignancy)

Malignancy

• Lymphomas (Hodgkin and non-Hodgkin) most common malignancy, accounting for 60–70% of cancers in A-T patients
• Gastric adenocarcinoma, breast cancer, ovarian cancer, and colorectal malignancy also significantly elevated
• Malignancies typically occur in second to third decade of life
• Presentation may be atypical and diagnosis often delayed due to attributed symptoms to underlying neurological disease

Clinical Diagnostic Criteria

• Progressive cerebellar ataxia with onset before age 10 years
• Oculomotor apraxia or progressive external ophthalmoplegia
• Conjunctival and/or cutaneous telangiectasias
• Immunodeficiency (lymphopenia, low immunoglobulin levels, or recurrent infections)
• Increased radiosensitivity and cancer predisposition
• Diagnostic confirmation requires ATM gene mutation analysis

Laboratory Testing

• Lymphocyte count: T-lymphopenia (particularly CD4+ and CD8+ cells reduced) in 80–90% of patients; B cells variably affected
• Serum immunoglobulins: IgA deficiency (most common, ~80%), IgE deficiency, variable hypogammaglobulinemia
• IgG subclass deficiencies: particularly IgG2 deficiency
• T-cell subset analysis: reduced naive T cells, elevated memory T-cell proportion
• Lymphocyte proliferation assays: reduced response to mitogens (PHA, ConA)

• Alpha-fetoprotein (AFP): markedly elevated (100–1000× normal) in >95% of patients; NOT associated with malignancy in A-T
• Chromosome breakage studies: Increased spontaneous chromosomal aberrations and breaks; amplified response to ionizing radiation (diagnostic test)
• ATM gene sequencing: Gold standard for diagnosis; identifies biallelic mutations
• ATM protein analysis: Western blot showing absent or truncated ATM protein (requires specialized laboratory)
• Radiosensitivity testing: Fibroblasts show excessive sensitivity to ionizing radiation (clonogenic survival assay)

Imaging Findings

• Brain MRI: Progressive cerebellar atrophy (most striking finding); cerebellar vermis hypoplasia or atrophy
• White matter changes, basal ganglia abnormalities, and brainstem atrophy in advanced disease
• Progressive global brain atrophy with advancing neurological dysfunction

• Annual or biannual PET-CT (controversially recommended given radiosensitivity)
• Serial chest X-rays for pulmonary malignancy screening
• Upper endoscopy and gastric biopsies for gastric cancer surveillance (debated)
• Regular mammography with caution regarding radiation exposure
• Colonoscopy and other site-specific surveillance based on family history

Differential Diagnosis Considerations

• Spinocerebellar ataxias (SCA): lack immunodeficiency, telangiectasias, AFP elevation
• Friedreich ataxia: different inheritance pattern, cardiac involvement, earlier symptom onset typically
• Cerebellar hypoplasia: static, non-progressive
• Niemann-Pick disease type C: vertical supranuclear gaze palsy but different biochemical markers
• Combined immunodeficiency syndromes: lack characteristic neurological features and telangiectasias

Disease-Modifying Therapy (Limited Options)

• No FDA-approved disease-modifying therapy currently exists; treatment is largely supportive and symptomatic
• Antioxidants (vitamin E, coenzyme Q10, N-acetylcysteine) theoretically beneficial but limited evidence; often offered empirically
• Dafadine (formerly AT007), a small molecule corrector of ATM splicing, shown promise in early trials; clinical development ongoing
• PARP inhibitors (e.g., olaparib) may enhance survival of ATM-deficient cells by synthetic lethality; clinical trial data emerging

Infection Prevention and Immunological Support

• Prophylactic antibiotics: Trimethoprim-sulfamethoxazole for PCP prophylaxis if CD4+ count <200 cells/μL
• Broad-spectrum antibiotic coverage during acute infections based on culture and susceptibility
• Antifungal and antiviral prophylaxis as indicated by specific immunologic defects

• Immunoglobulin replacement therapy (intravenous immunoglobulin [IVIG] or subcutaneous immunoglobulin [SCIG]): 400–600 mg/kg/month for patients with hypogammaglobulinemia and recurrent infections
• Improves infection frequency and severity but does not correct T-cell defects
• Response variable; efficacy monitored clinically and by reduction in infection rates

• Live attenuated vaccines contraindicated due to immunodeficiency
• Inactivated vaccines (influenza, pneumococcal, meningococcal) offered but may have reduced efficacy; timing optimized to periods of better immune function if possible
• Vaccine response monitoring recommended

Metabolic and Endocrine Management

• Insulin therapy required in majority with overt diabetes; aggressive glycemic control reduces microvascular complications
• Metformin as adjunctive agent if tolerated
• Regular monitoring of HbA1c and fasting glucose
• Dietary consultation and glucose monitoring essential

• Growth hormone replacement if deficiency documented (rare but can occur)
• Hormone replacement therapy for hypogonadism during adolescence and adulthood
• Nutritional support for growth retardation

Neurological Management

• Physical therapy and occupational therapy: Core interventions to maintain mobility, function, and independence as long as possible
• Assistive devices: Walkers, canes, wheelchairs as disease progresses
• Speech therapy for dysarthria management and swallowing assessment
• Vestibular rehabilitation for balance disturbances

• Benzodiazepines (e.g., lorazepam) for tremor and dystonia if significantly impairing
• Baclofen for spasticity if develops
• Anticholinergic agents if parkinsonian features predominate
• No pharmacotherapy halts progression of ataxia

Malignancy Surveillance and Management

• Annual clinical examinations with high index of suspicion for malignancy
• Limitation of ionizing radiation exposure (conventional CT avoided; MRI preferred)
• PET-CT (despite theoretical radiosensitivity concern) offered for surveillance, particularly if symptoms suggestive
• Upper endoscopy for gastric cancer screening (insufficient evidence for routine screening; considered if risk factors)
• Lymph node biopsies for abnormal nodes (lymphomas frequent)

• Chemotherapy: Standard regimens often tolerated but require dose modifications due to radiosensitivity; hematologic toxicity typically greater
• Radiation therapy: Generally contraindicated or used with extreme caution and modified dosing; alternatives (surgery, chemotherapy) preferred when possible
• Surgical resection primary treatment modality for solid tumors when feasible
• Multidisciplinary oncology consultation essential before initiating cancer-directed therapy

Monitoring and Follow-up

• Annual or biannual immunological assessment (lymphocyte subsets, immunoglobulin levels)
• Annual AFP levels (rising levels may indicate malignancy development despite absence of baseline elevation significance)
• Periodic assessment of hepatic and renal function (relevant to drug metabolism)
• HbA1c monitoring every 3–6 months if diabetic

• Neurological examination every 6–12 months to assess rate of deterioration and adjust supportive care
• Pulmonary function testing annually or as symptoms warrant (bronchiectasis, interstitial lung disease)
• Ophthalmologic evaluation for visual complications
• Assessment of nutritional status and swallowing function

Neurological Deterioration

• Progressive functional decline with loss of ambulation (typically by late adolescence/early adulthood)
• Severe dysarthria eventually rendering patient non-verbal or minimally communicative
• Cognitive decline in subset of patients (variable); dementia-like syndrome in advanced disease
• Autonomic dysfunction: orthostatic hypotension, urinary incontinence, erectile dysfunction

Pulmonary Complications

• Bronchiectasis: Chronic suppurative airway disease from recurrent infections and immunodeficiency; significant cause of morbidity and mortality
• Interstitial lung disease: Progressive fibrosis in subset; can develop independent of infection history
• Aspiration pneumonia: Risk increases with advancing dysphagia and dysarthria
• Chronic sinusitis and otitis media with recurrent exacerbations
• Respiratory failure from progressive neurological decline affecting respiratory muscles (late-stage complication)

Malignancy (Life-Threatening)

• Lymphomas: Most frequent malignancy; often aggressive behavior with poor prognosis
• Gastric adenocarcinoma: Frequently diagnosed at advanced stage; high mortality
• Breast cancer: Earlier onset than general population;

• The classic stem: a toddler with progressive gait ataxia beginning as soon as walking starts, later joined by oculomotor apraxia with compensatory head thrusts, then conjunctival telangiectasias. Remember the sequence — ataxia precedes telangiectasia by years, so absent telangiectasias in a 3-year-old does not exclude A-T.
• Single best next step in a child with unexplained childhood-onset ataxia: serum alpha-fetoprotein plus quantitative immunoglobulins. AFP is markedly and persistently elevated in nearly all patients and is the cheapest, highest-yield screen; confirm with **biallelic ATM sequencing** (germline testing per ACMG-endorsed practice). Elevated AFP here does not mean hepatoblastoma or germ cell tumor — that is the trap.
• Mechanism to state out loud: ATM kinase senses double-strand breaks and phosphorylates p53/CHK2/BRCA1. No ATM → no checkpoint arrest → chromosomal instability, Purkinje cell death, failed V(D)J resolution (T-cell defect, IgA deficiency), and radiosensitivity.
• The association examiners love: lymphoid malignancy. Any A-T patient with adenopathy, cytopenias, or B symptoms should be worked up for lymphoma/leukemia, and imaging should be MRI or ultrasound, not CT — ionizing radiation is genuinely harmful in ATM-deficient cells. Radiation therapy is avoided or radically modified.
• Vaccines: live attenuated vaccines (MMR, varicella, rotavirus, live attenuated influenza) are contraindicated in combined immunodeficiency per ACIP/IDSA immunocompromised-host guidance; inactivated vaccines are given but responses may be blunted.
• Carrier pearl: heterozygous ATM variants are a moderate-penetrance breast cancer risk allele — NCCN Genetic/Familial High-Risk Assessment guidelines support enhanced breast surveillance (annual mammography with consideration of breast MRI) in adult female carriers, who are otherwise neurologically normal.
• Common distractors: Friedreich ataxia (GAA repeat, hypertrophic cardiomyopathy, areflexia with upgoing toes, pes cavus, normal AFP, no telangiectasia); hereditary hemorrhagic telangiectasia (autosomal dominant, epistaxis, AVMs, no ataxia); Niemann-Pick C (vertical supranuclear gaze palsy, hepatosplenomegaly).
• Transfusion caveat: with severe IgA deficiency, anti-IgA antibodies can provoke anaphylactic transfusion reactions — washed cellular products are the answer.